152 related articles for article (PubMed ID: 33523584)
41. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
42. A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.
Wang K; Li J; Xiong YF; Zeng Z; Zhang X; Li HY
Sci Rep; 2018 Feb; 8(1):3179. PubMed ID: 29453409
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes.
Heimes AS; Härtner F; Almstedt K; Krajnak S; Lebrecht A; Battista MJ; Edlund K; Brenner W; Hasenburg A; Sahin U; Gehrmann M; Hengstler JG; Schmidt M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003293
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer.
Dugo M; Huang X; Iorio MV; Cataldo A; Tagliabue E; Daidone MG; Wu J; Orlandi R
Breast; 2018 Jun; 39():46-52. PubMed ID: 29597130
[TBL] [Abstract][Full Text] [Related]
46. Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
Pece S; Disalvatore D; Tosoni D; Vecchi M; Confalonieri S; Bertalot G; Viale G; Colleoni M; Veronesi P; Galimberti V; Di Fiore PP
EBioMedicine; 2019 Apr; 42():352-362. PubMed ID: 30846393
[TBL] [Abstract][Full Text] [Related]
47. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Elger T; Krajnak S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
Breast Cancer Res Treat; 2017 Sep; 165(2):293-300. PubMed ID: 28585074
[TBL] [Abstract][Full Text] [Related]
48. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
49. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
50. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
Front Immunol; 2020; 11():558757. PubMed ID: 33329517
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
52. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
53. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
54. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
[TBL] [Abstract][Full Text] [Related]
55. Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
Kang HW; Seo SP; Byun YJ; Piao XM; Kim YH; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2018 Aug; 16(4):274-280. PubMed ID: 29571585
[TBL] [Abstract][Full Text] [Related]
56. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
57. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment.
Chen Y; Meng Z; Zhang L; Liu F
Front Immunol; 2021; 12():664845. PubMed ID: 33968066
[TBL] [Abstract][Full Text] [Related]
58. Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.
Natrajan R; Sailem H; Mardakheh FK; Arias Garcia M; Tape CJ; Dowsett M; Bakal C; Yuan Y
PLoS Med; 2016 Feb; 13(2):e1001961. PubMed ID: 26881778
[TBL] [Abstract][Full Text] [Related]
59. Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.
Chen L; Jenjaroenpun P; Pillai AM; Ivshina AV; Ow GS; Efthimios M; Zhiqun T; Tan TZ; Lee SC; Rogers K; Ward JM; Mori S; Adams DJ; Jenkins NA; Copeland NG; Ban KH; Kuznetsov VA; Thiery JP
Proc Natl Acad Sci U S A; 2017 Mar; 114(11):E2215-E2224. PubMed ID: 28251929
[TBL] [Abstract][Full Text] [Related]
60. Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer.
Qi A; Ju M; Liu Y; Bi J; Wei Q; He M; Wei M; Zhao L
Pathol Oncol Res; 2021; 27():600727. PubMed ID: 34257557
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
